Isis Sees A “Fit” With Archemix In Developing Novel Oligonucleotide-Based Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms enter strategic alliance that provides Archemix access to four hundred Isis patents for developing proprietary aptamer therapeutics.
You may also be interested in...
Takeda, Merck KGaA Sign Aptamer Development Deals With Archemix
Archemix gets $6 million up-front in Takeda deal; Merck agrees to make $29.8 million equity investment in Cambridge, Mass. company.
Pfizer Invests In Potential New Drug Class
Aptamer therapeutics act like biologics but are chemically synthesized, according to Pfizer collaborator Archemix.
FDA On Lookout For “Shenanigans” In Nutritionals – Consultant
More FDA enforcement action is focusing on regulatory compliance by nutritional supplement firms in part because there is "plenty of room for shenanigans" in marketing the products, according to John Avellanet, a compliance consultant